Inogen (INGN) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month price objectives for Inogen's shares. Their INGN share price forecasts range from $8.00 to $26.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $19.71 at the beginning of the year. Since then, INGN stock has decreased by 72.8% and is now trading at $5.36.
View the best growth stocks for 2023 here.

Inogen saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 639,200 shares, an increase of 29.7% from the August 31st total of 492,900 shares. Based on an average trading volume of 277,300 shares, the short-interest ratio is currently 2.3 days.
View Inogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our INGN earnings forecast.

Inogen, Inc. (NASDAQ:INGN) issued its earnings results on Monday, August, 7th. The medical technology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.22. The medical technology company earned $83.64 million during the quarter, compared to the consensus estimate of $92.20 million. Inogen had a negative trailing twelve-month return on equity of 14.95% and a negative net margin of 27.57%. The business's quarterly revenue was down 19.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) earnings per share.

Inogen updated its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $315.00 million-$320.00 million, compared to the consensus revenue estimate of $316.73 million.

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $5.36.

Inogen (NASDAQ:INGN) has a market capitalization of $124.30 million and generates $377.24 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis.

The company employs 1,026 workers across the globe.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.